The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer

Cetuximab, fluorouracil and cisplatin with or without docetaxel

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin

Changes in neutrophile-to-lymphocyte ratio as predictive and

GEDEFO on X: Docetaxel can be substituted for 5-FU in combination

Radiotherapy plus cetuximab or cisplatin in human papillomavirus

Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic

Frontiers The Evolving Role of Taxanes in Combination With

Neoadjuvant cisplatin and fluorouracil versus epirubicin

Frontiers TTCC-2019-02: real-world evidence of first-line

Cetuximab, docetaxel, and cisplatin as first-line treatment in

Randomized Phase III Trial of Concurrent Accelerated Radiation